Medigen Vaccine Biologics Corp’s (高端疫苗) phase 3 clinical trials for an enterovirus 71 (EV71) vaccine completed the multi-regional, multi-central data “unblinding” yesterday, with the results, including safety, immunogenicity and efficacy, meeting its expectations.
The company would compile a final analysis report as soon as possible, and apply for the new drug certificate from domestic and foreign drug authorities in the third quarter, Medigen said in a Taiwan Stock Exchange filing yesterday.
Its phase 3 trials were conducted in Taiwan and Vietnam with 3,049 participants ranging from two months old to six years old, Medigen said.
Photo: Sam Yeh, AFP
The company enrolled its first participant for the phase 3 trials in April 2019 and completed the enrollment of all participants in December that year, it said.
Participants were recruited in a randomized, double-blinded and placebo-controlled study, it added.
Participants were divided into three age groups: two months to six months old, six months to two years old, and two years to six years old, Medigen said.
The number of infants from two months to six months old accounted for 25 percent of all participants, it said.
The results showed the drug’s safety and tolerance were good, even for young participants, and there was no significant difference in safety and tolerance between participants who were given the vaccine and those who received a placebo, the company said.
As for immunogenicity, results showed that the seroprotection rates 28 days, six months and one year after two EV71 vaccination doses were higher than health authorities’ requirements, it said. The seroprotection rates refer to the degree of antibody prevalence.
In terms of efficacy, Medigen said that the experimental drug offered statistically significant protection against the enterovirus under the Poisson regression model.
As enterovirus infections are popular in Taiwan, China and Southeast Asia, the company hopes its vaccine can hit the market soon, as there are no EV71 vaccine products available in other parts of the world, except for China.
At present, only three Chinese manufacturers have launched enterovirus vaccines to be marketed locally in China, Medigen said.
Those vaccines are suitable for children over the age of six months, it said.
In 2018, the market sales of China’s EV71 vaccines reached more than NT$30 billion (US$1.08 billion), and about 21 million doses were sold per year on average in the past three years, Medigen said.
The company on June 10 reported positive results from an interim analysis of phase 2 trials for its COVID-19 vaccine. It has applied to the Food and Drug Administration for emergency use authorization and is preparing to conduct phase 3 trials abroad.
SEEKING CLARITY: Washington should not adopt measures that create uncertainties for ‘existing semiconductor investments,’ TSMC said referring to its US$165 billion in the US Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) told the US that any future tariffs on Taiwanese semiconductors could reduce demand for chips and derail its pledge to increase its investment in Arizona. “New import restrictions could jeopardize current US leadership in the competitive technology industry and create uncertainties for many committed semiconductor capital projects in the US, including TSMC Arizona’s significant investment plan in Phoenix,” the chipmaker wrote in a letter to the US Department of Commerce. TSMC issued the warning in response to a solicitation for comments by the department on a possible tariff on semiconductor imports by US President Donald Trump’s
The government has launched a three-pronged strategy to attract local and international talent, aiming to position Taiwan as a new global hub following Nvidia Corp’s announcement that it has chosen Taipei as the site of its Taiwan headquarters. Nvidia cofounder and CEO Jensen Huang (黃仁勳) on Monday last week announced during his keynote speech at the Computex trade show in Taipei that the Nvidia Constellation, the company’s planned Taiwan headquarters, would be located in the Beitou-Shilin Technology Park (北投士林科技園區) in Taipei. Huang’s decision to establish a base in Taiwan is “primarily due to Taiwan’s talent pool and its strength in the semiconductor
An earnings report from semiconductor giant and artificial intelligence (AI) bellwether Nvidia Corp takes center stage for Wall Street this week, as stocks hit a speed bump of worries over US federal deficits driving up Treasury yields. US equities pulled back last week after a torrid rally, as investors turned their attention to tax and spending legislation poised to swell the US government’s US$36 trillion in debt. Long-dated US Treasury yields rose amid the fiscal worries, with the 30-year yield topping 5 percent and hitting its highest level since late 2023. Stocks were dealt another blow on Friday when US President Donald
UNCERTAINTY: Investors remain worried that trade negotiations with Washington could go poorly, given Trump’s inconsistency on tariffs in his second term, experts said The consumer confidence index this month fell for a ninth consecutive month to its lowest level in 13 months, as global trade uncertainties and tariff risks cloud Taiwan’s economic outlook, a survey released yesterday by National Central University found. The biggest decline came from the timing for stock investments, which plunged 11.82 points to 26.82, underscoring bleak investor confidence, it said. “Although the TAIEX reclaimed the 21,000-point mark after the US and China agreed to bury the hatchet for 90 days, investors remain worried that the situation would turn sour later,” said Dachrahn Wu (吳大任), director of the university’s Research Center for
RSS